PT534618E - Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b - Google Patents

Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b

Info

Publication number
PT534618E
PT534618E PT92307785T PT92307785T PT534618E PT 534618 E PT534618 E PT 534618E PT 92307785 T PT92307785 T PT 92307785T PT 92307785 T PT92307785 T PT 92307785T PT 534618 E PT534618 E PT 534618E
Authority
PT
Portugal
Prior art keywords
peptides
hbv
hepatitis
virus
citotoxic
Prior art date
Application number
PT92307785T
Other languages
English (en)
Inventor
Francis V Chisari
Ferrari Carlo
Penna Amalia
Missale Gabriele
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT534618E publication Critical patent/PT534618E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT92307785T 1991-08-26 1992-08-26 Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b PT534618E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
PT534618E true PT534618E (pt) 2006-08-31

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92307785T PT534618E (pt) 1991-08-26 1992-08-26 Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b

Country Status (19)

Country Link
EP (1) EP0534618B1 (pt)
JP (3) JP3566284B2 (pt)
AT (1) ATE320444T1 (pt)
AU (1) AU679901B2 (pt)
BG (1) BG98522A (pt)
CA (1) CA2115927C (pt)
CZ (1) CZ42894A3 (pt)
DE (1) DE69233607T2 (pt)
DK (1) DK0534618T3 (pt)
ES (1) ES2262132T3 (pt)
FI (1) FI940919A (pt)
HU (1) HUT67529A (pt)
IL (1) IL102963A0 (pt)
NO (1) NO940661L (pt)
NZ (2) NZ244102A (pt)
OA (1) OA09889A (pt)
PT (1) PT534618E (pt)
WO (1) WO1993003753A1 (pt)
ZA (1) ZA926440B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
WO1999036434A1 (en) * 1998-01-19 1999-07-22 Mogam Biotechnology Research Institute Liposomes comprising peptide antigens derived from x protein of hepatitis b virus
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
BR112017001162A2 (pt) * 2014-07-22 2017-11-14 Alios Biopharma Inc métodos para tratar paramixovírus
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
SG11202107510SA (en) * 2019-01-11 2021-08-30 Agency Science Tech & Res Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (pt) * 1972-08-25 1974-04-13
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
EP0534618A3 (en) 1993-06-30
WO1993003753A1 (en) 1993-03-04
CA2115927A1 (en) 1993-03-04
IL102963A0 (en) 1993-01-31
OA09889A (en) 1994-09-15
AU679901B2 (en) 1997-07-17
CA2115927C (en) 2009-04-21
NZ244102A (en) 1996-12-20
JP2003300999A (ja) 2003-10-21
CZ42894A3 (en) 1995-02-15
BG98522A (en) 1995-05-31
ATE320444T1 (de) 2006-04-15
EP0534618A2 (en) 1993-03-31
DE69233607D1 (de) 2006-05-11
ES2262132T3 (es) 2006-11-16
NO940661L (no) 1994-04-19
FI940919A (fi) 1994-04-25
DE69233607T2 (de) 2006-11-30
JPH06510050A (ja) 1994-11-10
EP0534618B1 (en) 2006-03-15
HUT67529A (en) 1995-04-28
FI940919A0 (fi) 1994-02-25
DK0534618T3 (da) 2006-07-24
JP2003267997A (ja) 2003-09-25
NO940661D0 (no) 1994-02-25
JP3566284B2 (ja) 2004-09-15
NZ270625A (en) 1996-12-20
JP3694300B2 (ja) 2005-09-14
HU9400582D0 (en) 1994-07-28
ZA926440B (en) 1993-06-07
AU2540892A (en) 1993-03-16
JP3694299B2 (ja) 2005-09-14

Similar Documents

Publication Publication Date Title
PT534618E (pt) Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b
EP0726758A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTHES TARGETED AGAINST THE HEPATITIS B-VIRUS
EP0687182A4 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST THE HEPATITIS B VIRUS
EP1018344A3 (en) HLA-restricted hepatitis B virus CTL epitopes
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
GB2255093A (en) Hiv-1 core protein fragments
Kaplan et al. Pathogenesis of rabies in immunodeficient mice
ATE45961T1 (de) Humanes cytomegalovirus immunserumglobulin mit hohem titer und verfahren zu seiner herstellung.
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
Sanadgol Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no?
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
ASANO STUDY ON THE HOST FACTORS INVOLVED IN PATHOGENICITY OF FOWL PLAGUE VIRUS
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.